Dennis J. Slamon
Affiliations: | University of California, Los Angeles, Los Angeles, CA |
Area:
Molecular Biology, Cell Biology, Oncology, PharmacologyGoogle:
"Dennis Slamon"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Slamon DJ, Fasching PA, Hurvitz S, et al. (2023) Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy endocrine therapy alone in patients with HR+/HER2- early breast cancer. Therapeutic Advances in Medical Oncology. 15: 17588359231178125 |
| Cobleigh MA, Vogel CL, Tripathy D, et al. (2023) Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 41: 1501-1510 |
| de Haas SL, Slamon DJ, Martin M, et al. (2023) Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). Breast Cancer Research : Bcr. 25: 2 |
| Wander SA, O'Brien N, Litchfield LM, et al. (2022) Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. The Oncologist |
| O'Brien NA, Huang HKT, McDermott MSJ, et al. (2022) Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies. Molecular Cancer Therapeutics. OF1-OF11 |
| Hurvitz SA, McAndrew NP, Bardia A, et al. (2021) A careful reassessment of anthracycline use in curable breast cancer. Npj Breast Cancer. 7: 134 |
| O'Brien NA, McDermott MSJ, Conklin D, et al. (2020) Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Research : Bcr. 22: 89 |
| Finn RS, Boer K, Bondarenko I, et al. (2020) Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Research and Treatment |
| Talhouk A, George J, Wang C, et al. (2020) Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Slamon DJ, Jerusalem G. (2020) Ribociclib plus Fulvestrant in Advanced Breast Cancer. Reply. The New England Journal of Medicine. 382: e85 |